IL-1β is a critical mediator of trained immunity and chronic inflammatory hepatopathies such as NASH and NAFLD, raising the question of the therapeutic targeting of the IL-1/IL-1R axis. The gene discussed is IL1A; the disease is metabolic dysfunction-associated steatotic liver disease.